HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012
New market study, "HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012", has been published
18.08.2012 15:56:20 - New Pharmaceuticals market report from Global Markets Direct: "HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012"
(live-PR.com) - Global Markets Direct's, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012', provides an overview of the HIV-Associated Lipodystrophy Syndrome therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. 'HIV-Associated
Lipodystrophy Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
------------------------------------------------------------
Full Report Details at
- www.fastmr.com/prod/449635_hivassociated_lipodys ..
------------------------------------------------------------
Scope
* A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
* A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
HIV-Associated Lipodystrophy Syndrome Therapeutic Products under Development, Key Players in HIV-Associated Lipodystrophy Syndrome Therapeutics, HIV-Associated Lipodystrophy Syndrome Pipeline Overview, HIV-Associated Lipodystrophy Syndrome Pipeline, HIV-Associated Lipodystrophy Syndrome Pipeline Assessment
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV-Associated Lipodystrophy Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development
Theratechnologies Inc.
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Egrifta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Serostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Growth Hormone + Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant IGF-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products
HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products
HIV-Associated Lipodystrophy Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin
Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela
Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=44 ..
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=103 ..
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.
|
|
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
------------------------------------------------------------
Full Report Details at
- www.fastmr.com/prod/449635_hivassociated_lipodys ..
------------------------------------------------------------
Scope
* A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
* A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
HIV-Associated Lipodystrophy Syndrome Therapeutic Products under Development, Key Players in HIV-Associated Lipodystrophy Syndrome Therapeutics, HIV-Associated Lipodystrophy Syndrome Pipeline Overview, HIV-Associated Lipodystrophy Syndrome Pipeline, HIV-Associated Lipodystrophy Syndrome Pipeline Assessment
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV-Associated Lipodystrophy Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development
Theratechnologies Inc.
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Egrifta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Serostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Growth Hormone + Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant IGF-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products
HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products
HIV-Associated Lipodystrophy Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin
Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela
Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=44 ..
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=103 ..
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.
| Author: |
